O. S. Adeyemi, Screening of chemical compound libraries identified new anti-Toxoplasma gondii agents, Parasitol. Res, vol.117, issue.2, pp.355-363, 2018.

W. Adriaensen, Immunomodulatory therapy of visceral leishmaniasis in human immunodeficiency virus-coinfected patients, Front. Immunol, vol.8, 2018.

M. A. Afifi and M. W. Al-rabia, The immunomodulatory effects of rolipram abolish drug-resistant latent phase of Toxoplasma gondii infection in a murine model, J. Microsc. Ultrastruct, vol.3, issue.2, pp.86-91, 2015.

P. H. Alday and J. S. Doggett, Drugs in development for toxoplasmosis: advances, challenges, and current status, Drug Des. Devel. Ther, vol.11, pp.273-293, 2017.

J. Arens, Treating AIDS-associated cerebral toxoplasmosis -pyrimethamine plus sulfadiazine compared with cotrimoxazole, and outcome with adjunctive glucocorticoids, S. Afr. Med. J, vol.97, issue.10, pp.956-958, 2007.

H. Baatz, Reactivation of Toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient, Ocul. Immunol. Inflamm, vol.14, issue.3, pp.185-187, 2006.

S. Bahrami, Potential application of nanochitosan film as a therapeutic agent against cutaneous leishmaniasis caused by L. major, Parasitol. Res, vol.114, issue.12, pp.4617-4624, 2015.

R. R. Ben-harari, E. Goodwin, and J. Casoy, Adverse event profile of pyrimethamine-based therapy in toxoplasmosis: a systematic review, Drugs in R&D, vol.17, issue.4, pp.523-544, 2017.

I. Benmerzouga, Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis, Antimicrob. Agents Chemother, vol.59, issue.11, pp.6939-6945, 2015.

R. Bhadra, H. Guan, and I. A. Khan, Absence of both IL-7 and IL-15 severely impairs the development of CD8 T cell response against Toxoplasma gondii, PLoS One, vol.5, issue.5, 2010.

R. Bhadra, J. P. Gigley, and I. A. Khan, The CD8 T-cell road to immunotherapy of toxoplasmosis, Immunotherapy, vol.3, issue.6, pp.789-801, 2011.

R. Bhadra, Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade, Proc. Natl. Acad. Sci. U. S. A, vol.108, issue.22, pp.9196-9201, 2011.

R. Bhadra, J. P. Gigley, and I. A. Khan, PD-1-mediated attrition of polyfunctional memory CD8+ T cells in chronic Toxoplasma infection, J. Infect. Dis, vol.206, issue.1, pp.125-134, 2012.

R. Bhadra, D. A. Cobb, and I. A. Khan, Donor CD8 + T cells prevent Toxoplasma gondii de-encystation but fail to rescue the exhausted endogenous CD8 + T cell population', Infection and Immunity, vol.81, pp.3414-3425, 2013.

L. H. Bosch-driessen, A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis, Am J. Ophthalmol, vol.134, issue.1, pp.34-40, 2002.

A. Bougdour, Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites, J. Exp. Med, vol.206, issue.4, pp.953-966, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00389147

F. F. Boyom, Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica, Antimicrob. Agents Chemother, vol.58, issue.10, pp.5848-5854, 2014.

N. J. Butler, Ocular toxoplasmosis II: clinical features, pathology and management, Clin. Exp. Ophthalmol, vol.41, issue.1, pp.95-108, 2013.

G. Cai, R. Kastelein, and C. A. Hunter, Interleukin-18 (IL-18) enhances innate IL-12-mediated resistance to Toxoplasma gondii, Infect. Immun, vol.68, issue.12, pp.6932-6938, 2000.

A. L. Campbell, First case of toxoplasmosis following small bowel transplantation and systematic review of tissue-invasive toxoplasmosis following noncardiac solid organ transplantation, Transplantation, vol.81, issue.3, pp.408-417, 2006.

D. Y. Cha, Effects of specific monoclonal antibodies to dense granular proteins on the invasion of Toxoplasma gondii in vitro and in vivo, Korean J. Parasitol, vol.39, issue.3, pp.233-240, 2001.

K. Chirgwin, Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039, Clin. Infect. Dis, vol.34, issue.9, pp.1243-1250, 2002.

H. Chung, Bilateral Toxoplasma Retinochoroiditis simulating cytomegalovirus retinitis in an allogeneic bone marrow transplant patient, Korean J. Ophthalmol, vol.22, issue.3, pp.197-200, 2008.

M. Cortina-borja, Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study, PLoS Med, vol.7, issue.10, 2010.

F. Daffos, Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis, N. Engl. J. Med, vol.318, issue.5, pp.271-275, 1988.

B. Dannemann, Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California collaborative treatment group, Ann. Intern. Med, vol.116, issue.1, pp.33-43, 1992.

M. De-kock, Population pharmacokinetic properties of sulfadoxine and pyrimethamine: a pooled analysis to inform optimal dosing in African children with uncomplicated malaria, Antimicrob. Agents Chemother, vol.62, issue.5, 2018.

M. Deckert-schlüter, Interleukin-10 downregulates the intracerebral immune response in chronic Toxoplasma encephalitis, J. Neuroimmunol, vol.76, issue.1, pp.47-54, 1997.

G. Desmonts and J. Couvreur, Toxoplasmosis in pregnancy and its transmission to the fetus, Bull. N. Y. Acad. Med, vol.50, issue.2, pp.146-159, 1974.

R. Dhakal, K. Gajurel, and J. G. Montoya, Toxoplasmosis in the non-orthotopic heart transplant recipient population, how common is it? Any indication for prophylaxis?, Curr. Opin. Organ Transplant, vol.23, issue.4, pp.407-416, 2018.

A. J. Dittmar, A. A. Drozda, and I. J. Blader, Drug repurposing screening identifies novel compounds that effectively inhibit Toxoplasma gondii growth', mSphere, p.1, 2016.

O. Djurkovi?-djakovi?, Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis, Antimicrob. Agents Chemother, vol.43, issue.9, pp.2240-2244, 1999.

O. Djurkovi?-djakovi?, Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii, J. Antimicrob. Chemother, vol.50, issue.6, pp.981-987, 2002.

R. Docampo, Lipid peroxidation and the generation of free radicals, superoxide anion, and hydrogen peroxide in beta-lapachone-treated Trypanosoma cruzi epimastigotes, Arch. Biochem. Biophys, vol.186, issue.2, pp.292-297, 1978.

J. S. Doggett, Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis, Proc. Natl. Acad. Sci. U. S. A, vol.109, issue.39, pp.15936-15941, 2012.

J. S. Doggett, Bumped kinase inhibitor 1294 treats established Toxoplasma gondii infection, Antimicrob. Agents Chemother, vol.58, issue.6, pp.3547-3549, 2014.

C. Doliwa, Identification of differentially expressed proteins in sulfadiazine resistant and sensitive strains of toxoplasma gondii using difference-gel electrophoresis (DIGE), Int. J. Parasitol, vol.3, pp.35-44, 2013.

I. R. Dunay, Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model, Antimicrob. Agents Chemother, vol.53, issue.10, pp.4450-4456, 2009.

I. R. Dunay, Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice, Clin. Microbiol. Rev, issue.4, 2018.

M. M. Eissa, Could miltefosine be used as a therapy for toxoplasmosis?, Exp. Parasitol, vol.157, pp.12-22, 2015.

L. A. El-zawawy, Preventive prospective of triclosan and triclosan-liposomal nanoparticles against experimental infection with a cystogenic ME49 strain of Toxoplasma gondii, Acta Trop, vol.141, pp.103-111, 2015.

L. A. El-zawawy, Triclosan and triclosan-loaded liposomal nanoparticles in the treatment of acute experimental toxoplasmosis, Exp. Parasitol, vol.149, pp.54-64, 2015.

S. Escotte-binet, Metallopeptidases of Toxoplasma gondii: in silico identification and gene expression, Parasite, vol.25, 2018.

S. E. Etewa, Assessment of spiramycin-loaded chitosan nanoparticles treatment on acute and chronic toxoplasmosis in mice, J. Parasit. Dis, vol.42, issue.1, pp.102-113, 2018.

, European AIDS Clinical Society (EACS), 2018.

D. J. Ferguson, An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii, Int. J. Exp. Pathol, vol.75, issue.2, pp.111-116, 1994.

N. Fernàndez-sabé, Risk factors, clinical features, and outcomes of toxoplasmosis in solid-organ transplant recipients: a matched case-control study, Clin. Infect. Dis, vol.54, issue.3, pp.355-361, 2012.

R. A. Ferreira, Activity of natural and synthetic naphthoquinones against Toxoplasma gondii, in vitro and in murine models of infection, Parasite, vol.9, issue.3, pp.261-269, 2002.

R. A. Ferreira, Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1?-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine, Exp. Parasitol, vol.113, issue.2, pp.125-129, 2006.

R. A. Ferreira, New naphthoquinones and an alkaloid with in vitro activity against Toxoplasma gondii RH and EGS strains, Exp. Parasitol, vol.132, issue.4, pp.450-457, 2012.

W. Foulon, Prenatal diagnosis of congenital toxoplasmosis: a multicenter evaluation of different diagnostic parameters, Am. J. Obstet. Gynecol, vol.181, issue.4, pp.843-847, 1999.

K. Freeman, Predictors of retinochoroiditis in children with congenital toxoplasmosis: European, prospective cohort study, Pediatrics, vol.121, issue.5, pp.1215-1222, 2008.

Y. Fu, Generation of a neutralizing human monoclonal antibody fab fragment to surface antigen 1 of Toxoplasma gondii tachyzoites, Infect. Immun, vol.79, issue.1, pp.512-517, 2011.

H. B. Fung and H. L. Kirschenbaum, Treatment regimens for patients with toxoplasmic encephalitis, Clin. Ther, vol.18, issue.6, pp.1037-1056, 1996.

K. Gajurel, R. Dhakal, and J. G. Montoya, Toxoplasma prophylaxis in haematopoietic cell transplant recipients: a review of the literature and recommendations, Curr. Opin. Infect. Dis, vol.28, issue.4, pp.283-292, 2015.

J. Gallant and A. Gallino, Get rich quick with old generic drugs! The Pyrimethamine pricing scandal, Eur. J. Clin. Microbiol. Infect. Dis, vol.2, issue.4, pp.389-393, 1996.

R. T. Gazzinelli, Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts, Proc. Natl. Acad. Sci. U. S. A, vol.90, issue.13, pp.6115-6119, 1993.

R. T. Gazzinelli, In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha, J. Immunol, vol.157, issue.2, pp.798-805, 1996.

R. Gilbert and L. Gras, Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii, BJOG, vol.110, issue.2, pp.112-120, 2003.

R. Goswami and . Prosad, Alternative treatment approach to cerebral toxoplasmosis in HIV/AIDS: experience from a resource-poor setting, Int. J. STD AIDS, vol.26, issue.12, pp.864-869, 2015.

L. Gras, Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres, Acta Paediatr, vol.94, issue.12, pp.1721-1731, 2005.

S. M. Hegab and S. A. Al-mutawa, Immunopathogenesis of toxoplasmosis, Clin. Exp. Med, vol.3, issue.2, pp.84-105, 2003.

A. V. Hernandez, A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option?, HIV Med, vol.18, issue.2, pp.115-124, 2017.

G. N. Holland and K. G. Lewis, An update on current practices in the management of ocular toxoplasmosis, Am J. Ophthalmol, vol.134, issue.1, pp.102-114, 2002.

A. Hotop, H. Hlobil, and U. Gross, Efficacy of rapid treatment initiation following primary Toxoplasma gondii infection during pregnancy, Clin. Infect. Dis, vol.54, issue.11, pp.1545-1552, 2012.

. Innes, A one health approach to vaccines against Toxoplasma gondii. Food Waterborne Parasitol, 2019.

S. Jackowski, Acetoacetyl-acyl carrier protein synthase. A target for the antibiotic thiolactomycin, J. Biol. Chem, vol.264, issue.13, pp.7624-7629, 1989.

J. M. Jacobson, Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS, AIDS, vol.15, issue.5, pp.583-589, 2001.

D. Kadri, The potential of quinoline derivatives for the treatment of Toxoplasma gondii infection, Exp. Parasitol, vol.145, pp.135-144, 2014.

J. E. Kaplan, Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV medicine Association of the Infectious Diseases Society of America, MMWR. Recommendations and Reports: Morbidity and Mortality Weekly Report. Recommendations and Reports, vol.58, pp.1-207, 2009.

S. Kasagi, S. Kawano, and S. Kumagai, PD-1 and autoimmunity, Crit. Rev. Immunol, vol.31, issue.4, pp.265-295, 2011.

C. Katlama, Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS, Clin. Infect. Dis, vol.22, issue.2, pp.268-275, 1996.

I. A. Khan and L. H. Kasper, IL-15 augments CD8+ T cell-mediated immunity against Toxoplasma gondii infection in mice, J. Immunol, vol.157, issue.5, pp.2103-2108, 1996.

I. A. Khan, T. Matsuura, and L. H. Kasper, Interleukin-12 enhances murine survival against acute toxoplasmosis, Infect. Immun, vol.62, issue.5, pp.1639-1642, 1994.

I. A. Khan, T. Matsuura, and L. H. Kasper, IL-10 mediates immunosuppression following primary infection with Toxoplasma gondii in mice, Parasite Immunol, vol.17, issue.4, pp.185-195, 1995.

I. A. Khan, Immune CD8(+) T cells prevent reactivation of Toxoplasma gondii infection in the immunocompromised host, Infect. Immun, vol.67, issue.11, pp.5869-5876, 1999.

F. Kieffer, Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis, Pediatr. Infect. Dis. J, vol.27, issue.1, pp.27-32, 2008.

S. Kongsaengdao, Randomized controlled trial of pyrimethamine plus sulfadiazine versus trimethoprim plus sulfamethoxazole for treatment of toxoplasmic encephalitis in AIDS patients, J. Int. Assoc. Phys. AIDS Care, vol.7, issue.1, pp.11-16, 2008.

B. Lai, Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections, Proc. Natl. Acad. Sci. U. S. A, vol.109, issue.35, pp.14182-14187, 2012.

M. Lebech, Feasibility of neonatal screening for Toxoplasma infection in the absence of prenatal treatment. Danish congenital toxoplasmosis study group, Lancet, vol.353, issue.9167, pp.1834-1837, 1999.

S. S. Lim, .. Othman, and R. Y. , Recent advances in Toxoplasma gondii Immunotherapeutics, Korean J. Parasitol, vol.52, issue.6, pp.581-593, 2014.

S. Lourido, Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma, Nature, vol.465, issue.7296, pp.359-362, 2010.

B. J. Luft, Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome, N. Engl. J. Med, vol.329, issue.14, pp.995-1000, 1993.

J. D. Lykins, CSGID solves structures and identifies phenotypes for five enzymes in Toxoplasma gondii, Front. Cell. Infect. Microbiol, vol.8, p.352, 2018.

Y. A. Maldonado and J. Read, Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States, Pediatrics, vol.139, issue.2, 2017.

L. Mandelbrot, Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial, Am. J. Obstet. Gynecol, vol.219, issue.4, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01987714

R. Martino, Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation, Clin. Infect. Dis, vol.40, issue.1, pp.67-78, 2005.
URL : https://hal.archives-ouvertes.fr/hal-02682912

E. S. Martins-duarte, Thiolactomycin analogues as potential anti-Toxoplasma gondii agents, Parasitol. Int, vol.58, issue.4, pp.411-415, 2009.

D. Maubon, Activity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: inhibition of stage conversion of the parasite cyst form and study of new derivative compounds, Antimicrob. Agents Chemother, vol.54, issue.11, pp.4843-4850, 2010.

J. Mazumdar, Apicoplast fatty acid synthesis is essential for organelle biogenesis and parasite survival in Toxoplasma gondii, Proc. Natl. Acad. Sci. U. S. A, vol.103, issue.35, pp.13192-13197, 2006.

D. C. Mcfadden, Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance, Mol. Biochem. Parasitol, vol.108, issue.1, pp.1-12, 2000.

M. M. Mcfarland, Review of experimental compounds demonstrating anti-Toxoplasma activity, Antimicrob. Agents Chemother, vol.60, issue.12, pp.7017-7034, 2016.

R. Mcleod, Outcome of treatment for congenital toxoplasmosis, 1981-2004: the national collaborative Chicago-based, congenital toxoplasmosis study, Clin. Infect. Dis, vol.42, issue.10, pp.1383-1394, 2006.

M. Mcphillie, New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections, Sci. Rep, vol.6, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01440759

A. Mele, Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature, Bone Marrow Transplant, vol.29, issue.8, pp.691-698, 2002.

P. Meneceur, In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone, Antimicrob. Agents Chemother, vol.52, issue.4, pp.1269-1277, 2008.

M. B. Mets, Eye manifestations of congenital toxoplasmosis, Am J. Ophthalmol, vol.122, issue.3, pp.309-324, 1996.

M. Montazeri, A systematic review of in vitro and in vivo activities of anti-Toxoplasma drugs and compounds, Front. Microbiol, vol.8, 2006.

J. G. Montoya and O. Liesenfeld, Toxoplasmosis. Lancet, vol.363, issue.9425, pp.1965-1976, 2004.

E. J. Mui, Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo, PLoS Negl. Trop. Dis, vol.2, issue.3, 2008.

J. Müller, Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis, J. Antimicrob. Chemother, vol.72, issue.8, pp.2334-2341, 2017.

Y. Murata, Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites, PLoS One, vol.12, issue.6, 2017.

A. D. Ni-nyoman and C. G. Lüder, Apoptosis-like cell death pathways in the unicellular parasite Toxoplasma gondii following treatment with apoptosis inducers and chemotherapeutic agents: a proof-of-concept study, Apoptosis, vol.18, issue.6, pp.664-680, 2013.

J. M. O'donnell and H. Zhang, Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4), Trends Pharmacol. Sci, vol.25, issue.3, pp.158-163, 2004.

K. K. Ojo, A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation, J. Infect. Dis, vol.209, issue.2, pp.275-284, 2014.

D. Opsenica, Tetraoxanes as inhibitors of apicomplexan parasites Plasmodium falciparum and Toxoplasma gondii and anti-cancer molecules, J. Serb. Chem. Soc, vol.80, issue.11, pp.1339-1359, 2015.

C. Ozgonul and C. G. Besirli, Recent developments in the diagnosis and treatment of ocular toxoplasmosis, Ophthalmic Res, vol.57, issue.1, pp.1-12, 2017.

D. V. Patel, Resolution of intracranial calcifications in infants with treated congenital toxoplasmosis, Radiology, vol.199, issue.2, pp.433-440, 1996.

E. Petersen, Prevention and treatment of congenital toxoplasmosis, Expert Rev. Anti-Infect. Ther, vol.5, issue.2, pp.285-293, 2007.

F. Peyron, Congenital toxoplasmosis in France and the United States: one parasite, two diverging approaches, PLoS Negl. Trop. Dis, vol.11, issue.2, 2017.

A. W. Pfaff, New clinical and experimental insights into Old World and neotropical ocular toxoplasmosis, Int. J. Parasitol, vol.44, issue.2, pp.99-107, 2014.

L. Phan, Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life, Am J. Ophthalmol, vol.146, issue.3, pp.375-384, 2008.

A. Prusa, Amniocentesis for the detection of congenital toxoplasmosis: results from the nationwide Austrian prenatal screening program, Clin. Microbiol. Infect, vol.21, issue.2, pp.191-192, 2015.

J. B. Radke, Evaluation of current and emerging antimalarial medicines for inhibition of Toxoplasma gondii growth in Vitro, ACS Infect. Dis, vol.4, issue.8, pp.1264-1274, 2018.

S. Rajapakse, Antibiotics for human toxoplasmosis: a systematic review of randomized trials, Pathog. Glob. Health, vol.107, issue.4, pp.162-169, 2013.

S. Ramakrishnan, The intracellular parasite Toxoplasma gondii depends on the synthesis of long-chain and very long-chain unsaturated fatty acids not supplied by the host cell, Mol. Microbiol, vol.97, issue.1, pp.64-76, 2015.

F. Rezaei, A systematic review of Toxoplasma gondii antigens to find the best vaccine candidates for immunization, Microb. Pathog, vol.126, pp.172-184, 2018.

F. Robert-gangneux, It is not only the cat that did it: how to prevent and treat congenital toxoplasmosis, S125-S133, vol.68, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00875492

F. Robert-gangneux, Molecular diagnosis of toxoplasmosis in immunocompromised patients: a 3-year multicenter retrospective study, J. Clin. Microbiol, vol.27, issue.12, pp.1677-1684, 2011.

F. Robert-gangneux, Toxoplasmosis in transplant recipients, Emerg. Infect. Dis, vol.24, issue.8, pp.1497-1504, 2010.
URL : https://hal.archives-ouvertes.fr/hal-02456514

S. Romand, M. Pudney, F. Derouin, and A. Rothova, In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii, Antimicrob. Agents Chemother, vol.37, issue.11, pp.517-523, 1993.

F. U. Rutaganira, Inhibition of calcium dependent protein kinase 1 (CDPK1) by pyrazolopyrimidine analogs decreases establishment and reoccurrence of central nervous system disease by Toxoplasma gondii, J. Med. Chem, vol.60, issue.24, pp.9976-9989, 2017.

J. Saba, Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS, Eur. J. Clin. Microbiol. Infect. Dis, vol.12, issue.11, pp.853-856, 1993.

D. R. Schmidt, The national neonatal screening programme for congenital toxoplasmosis in Denmark: results from the initial four years, Arch. Dis. Child, vol.91, issue.8, pp.661-665, 1999.

F. L. Schuster, B. J. Guglielmo, and G. S. Visvesvara, In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri, J. Eukaryot. Microbiol, vol.53, issue.2, pp.121-126, 2006.

H. M. Shubar, A new combined flow-cytometry-based assay reveals excellent activity against Toxoplasma gondii and low toxicity of new bisphosphonates in vitro and in vivo, J. Antimicrob. Chemother, vol.61, issue.5, pp.1110-1119, 2008.

L. M. Signorell, Cord blood screening for congenital toxoplasmosis in northwestern Switzerland, Pediatr. Infect. Dis. J, vol.25, issue.2, pp.123-128, 1982.

L. A. Silva, Genetic polymorphisms and phenotypic profiles of sulfadiazine-resistant and sensitive Toxoplasma gondii isolates obtained from newborns with congenital toxoplasmosis in Minas Gerais, Brazil. PLoS One, vol.12, issue.1, 2017.

J. Spalenka, Discovery of new inhibitors of Toxoplasma gondii via the pathogen box, Antimicrob. Agents Chemother, vol.62, issue.2, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01995050

F. Tan, Monoclonal antibodies against nucleoside triphosphate hydrolase-II can reduce the replication of Toxoplasma gondii, Parasitol. Int, vol.59, issue.2, pp.141-146, 2010.

A. Teimouri, Anti-Toxoplasma activity of various molecular weights and concentrations of chitosan nanoparticles on tachyzoites of RH strain, Int. J. Nanomedicine, vol.13, pp.1341-1351, 2018.

R. Thiébaut, Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data, Lancet, vol.369, issue.9556, pp.115-122, 2007.

P. R. Torgerson and P. Mastroiacovo, The global burden of congenital toxoplasmosis: a systematic review, Bull. World Health Organ, vol.91, issue.7, pp.501-508, 2013.

D. Torre, Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian collaborative study group, Antimicrob. Agents Chemother, vol.42, issue.6, pp.1346-1349, 1998.

R. A. Torres, Atovaquone for salvage treatment and suppression of Toxoplasmic encephalitis in patients with AIDS, Clin. Infect. Dis, vol.24, issue.3, pp.422-429, 1997.

P. Valentini, Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy, Eur. J. Clin. Microbiol. Infect. Dis, vol.28, issue.3, pp.297-300, 2009.

R. S. Vidadala, Development of an orally available and central nervous system (CNS) penetrant Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitor with minimal human ether-a-go-go-related gene (hERG) activity for the treatment of toxoplasmosis, J. Med. Chem, vol.59, issue.13, pp.6531-6546, 2016.

I. Villena, Pyrimethamine-sulfadoxine treatment of congenital toxoplasmosis: follow-up of 78 cases between 1980 and 1997. Reims toxoplasmosis group. Scand, J. Infect. Dis, vol.30, issue.3, pp.295-300, 1998.

M. Wallon, Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years, Clin. Infect. Dis, vol.56, issue.9, pp.1223-1231, 2013.

Z. Wang, Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis, Lancet HIV, vol.4, issue.4, pp.177-188, 2017.

D. Webster, Treatment of granulomatous amoebic encephalitis with voriconazole and miltefosine in an immunocompetent soldier, Am. J. Trop. Med. Hyg, vol.87, issue.4, pp.715-718, 2012.

H. Wei, A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans, PLoS One, vol.10, issue.9, 2015.

C. B. Wilson, Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection, Pediatrics, vol.66, issue.5, pp.767-774, 1980.

G. Yap, M. Pesin, and A. Sher, Cutting edge: IL-12 is required for the maintenance of IFN-gamma production in T cells mediating chronic resistance to the intracellular pathogen, Toxoplasma gondii, J. Immunol, vol.165, issue.2, pp.628-631, 2000.

F. Yarovinsky, Innate immunity to Toxoplasma gondii infection, Nat. Rev. Immunol, vol.14, issue.2, pp.109-121, 2014.

C. You, Silver nanoparticle loaded collagen/chitosan scaffolds promote wound healing via regulating fibroblast migration and macrophage activation, Sci. Rep, vol.7, issue.1, 2017.